Figure S3 (related to Figure 3 and 4): (A) MHF1-MHF2 binds Holliday junction preferentially.
Purified 85, 120, 155, 190, 225, 270, and 305 nM) was incubated with the mixture of radiolabeled double-stranded DNA and Holliday junction with 150 mM KCl present. Data quantification is shown in the bar graph. (B) MHF1, MHF2, and MHF1-MHF2 lack DNA branch migration activity. MHF1 or MHF2 or MHF1-MHF2 dimer (100 nM each) is devoid of DNA branch migration activity. ATP was present in all the reactions. NP -no protein control. 40, 80 , and 100 nM) or MHF1 80, 120, and 240 nM) was tested with the dsDNA substrate, as described elsewhere. Some of the results were plotted. (B) DNA branch migration by FANCM was tested alone or with MHF1-MHF2 or MHF1 R110X -MHF2, as before. 
Supplemental Experimental Procedures
Cells, cell culture, chemical and drug sensitivity assays HeLa, HeLa S3 and HT1080 cells were maintained using standard procedures. EUFA867, EUFA867+FANCA, EUFA867+FANCA/FANCM, EUFA867+FANCA/delFANCM cell lines have been described earlier (Singh et al., 2009 ). Hydroxyurea (Sigma) was resuspended in water to a stock concentration of 1 M.
Mitomycin C (Sigma) was dissolved in 70% ethanol (Sigma) to a stock concentration of 250 ng/μL. Camptothecin (Sigma) was dissolved in DMSO (Sigma) to stock concentration of 10 mM. For drug sensitivity assay, 200 cells were seeded per 10cm dish containing the indicated concentration (in Fig. 3C and D) of MMC or camptothecin in DMEM medium (Invitrogen). After 10 days, cells were fixed, stained, and visible colonies were counted.
Cloning, constructs and retroviruses
The pMIEG3 retroviral vector has been described (Singh et al., 2008) . In order to generate a doubly-tagged FANCM construct, FANCM was PCR-amplified from pIRES-FANCM (Meetei et al., 2005) using the high fidelity pfu Polymerase (Stratagene) and Nterminal (His)6 and FLAG-tags were introduced by using PCR and cloned into pMIEG3 vector to generate pMIEG3-HF-FANCM. Human MHF1 (GenBank accession no. NM_199294) and MHF2 cDNA were obtained from Open Biosystems. MHF1 ORF was PCR-amplified with an amino-terminal (His)6-FLAG-tag. This product was cloned into the EcoRI and XhoI sites of the pMIEG3 vector to generate pMIEG3-HF-MHF1. MHF1 R110X was PCR-amplified with an amino-terminal FLAG-tag using pGEX-Bicis-GST-MHF1 R110X -(His) 6 -MHF2 as template. This product was cloned into the EcoRI and XhoI sites of the pMIEG3 vector to generate pMIEG3-FLAG-MHF1 R110X . Retroviral packaging and generation of stable cell lines were as described earlier (Singh et al., 2008) .
Full-length FANCM cDNA was cloned into pENTR/TEV/D-Topo vector using the Gateway system and then transferred, using Clonase reaction, into the pDEST20 destination vector for expression in insect cells. PCR was used to introduce a FLAG tag at the C-terminus of FANCM sequence. This expression vector was used to prepare recombinant viral particles according to the manufacturer's instructions (Invitrogen).
pDEST20-FANCM vector was used as a template to produce pDEST20-FANCM K117R
using QuickChange Site-Directed Mutagenesis kit (Stratagene). Similar to the protocol used for FANCM, this expression vector was used to prepare recombinant viral particles according to the manufacturer's instructions.
MHF1 and MHF2 were cloned into BamHI-XhoI sites and NdeI-NotI sites, respectively, of pGEX-bicis vector (Ciccia et al., 2007) . The R110X mutation was introduced into MHF1 using the QuickChange Site-Directed Mutagenesis kit (Stratagene) and pGEX-Bicis-GST-MHF1-(His) 6 -MHF2 as the template . The thrombin recognition site present in this vector was replaced with a TEV (Tobacco Etch Virus) protease recognition site by QuickChange Site-Directed Mutagenesis kit (Stratagene) for efficient GST cleavage. MHF1 alone and MHF2 alone were cloned into EcoRI-HindIII sites and EcoRI-SalI sites, respectively, of pMAL-p2X vector (New England Biolabs) for expression and purification of these proteins for antibody production.
Purification and mass spectrometry analyses of FANCM and MHF1 complexes
FANCM and MHF1 complexes were isolated from HT1080-HF-FANCM and HeLa S3-HF-MHF1 nuclear extracts, respectively, by using a modified two-step affinity chromatography protocol described previously (Singh et al., 2008) . The purified protein complex was resolved on an 8-16% SDS-PAGE gel and stained by either SilverQuest silver or colloidal blue staining kit according to the manufacturer's instructions (Invitrogen). Protein identification by Mass Spectrometry was carried out by using either excised gel pieces or the entire gel, as described previously (Meetei et al., 2003) . Actual MS data will be made available upon request.
Preparation of cellular fractions
Cellular fractionation was carried out as previously described (Kim et al., 2008) .
Briefly, cells were grown on 15-cm-diameter culture dishes and were exposed to HU (1 mM) or MMC (100 ng/mL) for 16 h. Cells were trypsinized and washed with cold phosphate-buffered saline (PBS; Invitrogen), and the pellets were resuspended in cold buffer A (10 mM PIPES, pH 7, 100 mM NaCl, 1 mM EGTA, 300 mM sucrose, protease inhibitor cocktail (Roche), 1 mM phenylmethylsulfonyl fluoride [PMSF]) containing 0.5% Triton X-100 (Sigma) and were incubated at room temperature (RT) for 2 min to permeabilize the cells. The suspension was then centrifuged at 300g for 3 min at 4 o C, and the supernatant (S2; detergent-soluble nuclear proteins) was collected and frozen. Pellets were washed with cold buffer A. Nuclei were then digested with RNase-free DNase I (200 U/mL) (Roche) in buffer A for 30 min at RT. The residual pellet was collected by centrifugation as described above. The supernatant (S3; DNase I-sensitive proteins) was frozen, and the pellets were boiled with 2XSDS buffer (P; pellet). Cell-equivalent volumes from each cell fraction were separated by SDS-PAGE and immunoblotted with antibodies.
FANCD2 immunofluorescence
Cells were grown on 12-mm-diameter glass coverslips, which were coated with poly-D-lysine, for a minimum of 24 hr prior to treatment or fixation. Cells were left untreated or were exposed to 2 mM HU or 100ng/mL MMC for 16 hr. 
Chromosome breakage and sister chromatid assays:
Cytogenetic analysis was carried out as described earlier (Killen et al., 2009; Meetei et al., 2003) .
Gel filtration analysis:
For gel filtration analysis, 5 mL of the HeLa S3 nuclear extract was made from 10
x 145 mm confluent dishes by lysing cells in 300 mM lysis buffer. The lysate was applied directly to a Superose 6 column (XK 26/70; Amersham) equilibrated with column running buffer containing 20 mM HEPES (pH 7.9), 300 mM NaCl, and 5% glycerol. We collected fractions of 4.5 mL and analyzed them (20 μL each) by SDS−PAGE (8−16%
gradient Tris-glycine gel; Invitrogen) and immunoblotting.
Computational analysis:
Likely orthologues of human MHF2 and MHF1 were identified by searching protein/nucleotide sequence databases available at NCBI using the BLAST program.
Multiple sequence alignment of the protein sequences was carried out using the MAFFT v6.240 program, which is available at http://align.genome.jp/mafft/. For the alignment, the G-INS-I strategy was used, with BLOSUM62 scoring matrix, Gap opening penalty of 1.5, and Offset value of 0.14. Shading of the multiple sequence alignment was carried out using the BOXSHADE 3.21 program available at http://www.ch.embnet.org/software/BOX_form.html. Putative domains were predicted using the InterProScan program available at http://www.ebi.ac.uk/Tools/InterProScan/.
Secondary structure (three alpha helices) characteristics of the histone fold were predicted using the Jpred3 server available at http://www.compbio.dundee.ac.uk/wwwjpred/index.html.
Purification of FANCM and FANCM K117R :
Purification of GST-FANCM-FLAG and GST-FANCM K117R -FLAG was carried out using the same procedure. Proteins were expressed in High-Five insect cells collected 48 h post-infection and resuspended in buffer A containing 50 mM Na2HPO4/NaH2PO4 (pH 7.0), 150 mM NaCl, 10 % glycerol, 0.1 % NP-40, 0.5 mM EDTA, 2 mM TCEP and protease inhibitors (Roche), as described by (Gari et al., 2008) b. The cell resuspension was sonicated on ice for 1 min at output 5 and 50 % duty cycle (Branson Sonifier) and the lysate was clarified by ultracentrifugation (100,000 x g for 90 min). The supernatant was incubated with 1 mL of anti-FLAG M2-agarose beads (Sigma) for 2 hours at 4°C
with mixing. The mixture was poured into a glass column, and the beads were washed with 100 mL of buffer A supplemented with 100 mM L-Arginine (pH 7.0) and with 100 mL of buffer A. GST-FANCM-FLAG or GST-FANCM K117R -FLAG was eluted in buffer A containing 100 μg/mL FLAG-peptide (Sigma) using a 30 min incubation with mixing.
The elution fractions were analyzed by SDS-PAGE, and the fractions containing FANC protein were combined and incubated overnight with 1 mL of GST Sepharose 4 Fast Flow beads (GE Healthcare). The mixture was transferred into a glass column, and the beads were washed with 50 mL buffer A. The bound proteins were eluted with buffer A containing 25 mM reduced glutathione. Fractions containing GST-FANCM-FLAG or GST-FANCM K117R -FLAG were pooled and dialyzed against 50 mM Na2HPO4/NaH2PO4 (pH 7.0), 150 mM NaCl, 10 % glycerol, 0.01 % NP-40, 0.5 mM EDTA, 1 mM TCEP, and stored in aliquots at -80°C.
Purification of MHF1-(His) 6 -MHF2:
All the purification steps were conducted at 0-4°C. The elution of the protein complex was monitored by 15% SDS-PAGE and Coomassie Blue staining. E .coli This solution was applied onto a 1 mL column of hydroxyapatite resin (BioRad), which was developed with a 30 mL gradient of 0-360 mM KH 2 PO 4 in buffer K. MHF1-(His) 6 -MHF2 was eluted from the hydroxyapatite column at 100 mM-160 mM KH 2 PO 4 . The peak fractions were pooled and diluted 1:4 with buffer K, before being further fractionated in a 1 mL Mono Q column with a 30 mL gradient of 100-500 mM KCl in buffer K. MHF1-(His) 6 -MHF2 was eluted from Mono Q at ~230 mM KCl. The eluted protein was concentrated to 0.5 mL (Amicon-10K concentrator, Millipore) and loaded on a Superdex 200 gel filtration column (24 mL) equilibrated and run in buffer K containing 150 mM KCl. Fractions containing highly purified MHF1-(His) 6 -MHF2 were concentrated and stored at -80°C.
Purification of MHF1 R110X -MHF2 mutant
The mutant protein complex was expressed and purified to near homogeneity as described for the wild type counter part.
Purification of MBP-MHF1 and MBP-MHF2
Purification of MBP-MHF1 and MBP-MHF2 was carried out using the same 
DNA substrates
Radiolabeled substrates were prepared with Oligonucleotides H3, H5, H7 and H8
(Integrated DNA Technology), as previously described (Longerich et al., 2009 Radiolabeled substrates for the branch migration assays were prepared as described (Gari et al., 2008) .
Affinity pull-down assays
For pull-down assays, GST-FANCM K117R -FLAG (250 ng 
